Aardvark Therapeutics, Inc. (NASDAQ:AARD) Cantor Fitzgerald Global Healthcare Conference 2025 September 3, 2025 11:30 AM EDT
Company Participants
Tien-Li Lee – CEO, Secretary & Director
Conference Call Participants
Joshua Schimmer – Cantor Fitzgerald & Co., Research Division
Presentation
Joshua Schimmer
Biotech Equity Research Analyst
All right. I think we’re ready to get started with our next session. I’m Josh Schimmer from the Cantor Biotech Equity Research team. Very pleased to introduce from Aardvark Therapeutics, Tien Lee, Chief Executive Officer and Founder. Tien, give us a quick snapshot of Aardvark, and we’ll then dive into all things, TAS2R agonists.
Tien-Li Lee
CEO, Secretary & Director
Okay. Great. Yes.
Joshua Schimmer
Biotech Equity Research Analyst
And by the way, Tien’s birthday is today. No better way than to celebrate with us, right?
Tien-Li Lee
CEO, Secretary & Director
Thank you. Thank you, Josh. Appreciate it. Yes. So Aardvark is a San Diego-based biotech company. We’re focused on small molecule drug development. We have a unique category of drugs. It’s a gut-brain signaling drug. It’s small molecule oral, but it’s gut restricted and it mostly stays in your gut, but it’s signaling gut-brain pathway to mediate a bunch of things, including abrogating hunger.
Question-and-Answer Session
Joshua Schimmer
Cantor Fitzgerald & Co., Research Division
And maybe talk a little bit about that pathway, right? So you consume something bitter, now its taste mess, you don’t taste it. And yet it gets into the stomach. What’s it signaling? What are kind of these upstream effects that ultimately impact appetite?
Tien-Li Lee
CEO, Secretary & Director
Sure, sure. First off, it’s counterintuitive, but you have taste receptors in your gut, not just your mouth. And as you mentioned, we bypass the oral cavity, so you don’t want to taste our drug in your mouth. And it’s hitting enteroendocrine cells, which are the cells that help regulate eating behavior. And
Read the full article here